A meta-Analysis of randomized controlled trials of telmisartan for flow-mediated dilatation

Hypertension Research

Volumn 37, Issue 9, 2014, Pages 845-851

  Takagi, Hisato ^a   Umemoto, Takuya ^a  

^a SHIZUOKA MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TELMISARTAN; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE;

ARTICLE; BLOOD VESSEL PARAMETERS; CONTROLLED CLINICAL TRIAL (TOPIC); ENDOTHELIAL DYSFUNCTION; FLOW MEDIATED DILATATION; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT DURATION; DRUG EFFECTS; VASCULAR ENDOTHELIUM; VASODILATATION;

ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; ENDOTHELIUM, VASCULAR; HUMANS; VASODILATION;

EID: 84910146230     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2014.81     Document Type: Article

References (58)

1. Balakumar P, Kathuria S. Submaximal PPARg activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders. Br J Pharmacol 2012; 166: 1981-1992.
2. Kurtz TW. Treating the metabolic syndrome: telmisartan as a peroxisome proliferatoractivated receptor-gamma activator. Acta Diabetol 2005; 42(Suppl 1): S9-S16.
3. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002.
4. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-Activated receptor-gamma activity. Circulation 2004; 109: 2054-2057.
5. Kurtz TW, Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-Angiotensin system. J Hypertens 2004; 22: 2253-2261.
6. Perl S, Schmölzer I, Sourij H, Pressl H, Eder M, Zweiker R, Wascher TC. Telmisartan improves vascular function independently of metabolic and antihypertensive effects in hypertensive subjects with impaired glucose tolerance. Int J Cardiol 2010; 139: 289-296.
7. Kishi T, Hirooka Y, Konno S, Sunagawa K. Angiotensin II receptor blockers improve endothelial dysfunction associated with sympathetic hyperactivity in metabolic syndrome. J Hypertens 2012; 30: 1646-1655.
8. Hu ZP, Wang BN, Qian HY, Zhou Q, Wei W, Wang Y. Fixed-dose telmisartan/ hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in decreasing serum hepatocyte growth factor and improving endothelial dysfunction in hypertensive patients. Int Heart J 2010; 51: 252-258.
9. Tomiyama H, Yamada J, Koji Y, Shiina K, Yoshida M, Yamashina A. Effect of telmisartan on forearm postischemic hyperemia and serum asymmetric dimethylarginine levels. Am J Hypertens 2007; 20: 1305-1311.
10. Inaba Y, Chen JA, Bergmann SR. Prediction of future cardiovascular outcomes by flowmediated vasodilatation of brachial artery: a meta-Analysis. Int J Cardiovasc Imag 2010; 26: 631-640.
11. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809.
12. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007; 115: 1285-1295.
13. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl JMed 2005; 352: 1685-1695.
14. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-1115.
15. Higgins JP, Deeks JJ, Altman DG. Chapter 16: special topics in statistics. In: Higgins JP and Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011, available from: www.cochrane-handbook.org. Last accessed on 1 February 2014.
16. Follmann D, Elliott P, Suh I, Cutler J. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 1992; 45: 769-773.
17. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
18. Lim SY, Kim SW, Kim EJ, Kang JH, Kim SA, Kim YK, Na JO, Choi CU, Lim HE, Han SW, Rha SW, Park CG, Seo HS, Oh DJ. Telmisartan versus valsartan in patients with hypertension: effects on cardiovascular, metabolic, and inflammatory parameters. Korean Circ J 2011; 41: 583-589.
19. Zankl AR, Ivandic B, Andrassy M, Volz HC, Krumsdorf U, Blessing E, Katus HA, Tiefenbacher CP. Telmisartan improves absolute walking distance and endothelial function in patients with peripheral artery disease. Clin Res Cardiol 2010; 99: 787-794.
20. Pelliccia F, Pasceri V, Cianfrocca C, Vitale C, Speciale G, Gaudio C, Rosano GM, Mercuro G. Angiotensin II receptor antagonism with telmisartan increases number of endothelial progenitor cells in normotensive patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. Atherosclerosis 2010; 210: 510-515.
21. Benndorf RA, Appel D, Maas R, Schwedhelm E, Wenzel UO, Böger RH. Telmisartan improves endothelial function in patients with essential hypertension. J Cardiovasc Pharmacol 2007; 50: 367-371.
22. Morimoto S, Yano Y, Maki K, Sawada K. Renal and vascular protective effects of telmisartan in patients with essential hypertension. Hypertens Res 2006; 29: 567-572.
23. Ghiadoni L, Magagna A, Versari D, Kardasz I, Huang Y, Taddei S, Salvetti A. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003; 41: 1281-1286.
24. Green DJ, Jones H, Thijssen D, Cable NT, Atkinson G. Flow-mediated dilation and cardiovascular event prediction: does nitric oxide matter? Hypertension 2011; 57: 363-369.
25. Meyer B, Mörtl D, Strecker K, Hülsmann M, Kulemann V, Neunteufl T, Pacher R, Berger R. Flow-mediated vasodilation predicts outcome in patients with chronic heart failure: comparison with B-type natriuretic peptide. J Am Coll Cardiol 2005; 46: 1011-1018.
26. Neunteufl T, Heher S, Katzenschlager R, Wölfl G, Kostner K, Maurer G, Weidinger F. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am J Cardiol 2000; 86: 207-210.
27. Gokce N, Keaney Jr JF, Hunter LM, Watkins MT, Nedeljkovic ZS, Menzoian JO, Vita JA. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 2003; 41: 1769-1775.
28. Fathi R, Haluska B, Isbel N, Short L, Marwick TH. The relative importance of vascular structure and function in predicting cardiovascular events. J Am Coll Cardiol 2004; 43: 616-623.
29. Brevetti G, Silvestro A, Schiano V, Chiariello M. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index. Circulation 2003; 108: 2093-2098.
30. Karatzis EN, Ikonomidis I, Vamvakou GD, Papaioannou TG, Protogerou AD, Andreadou I, Voidonikola PT, Karatzi KN, Papamichael CM, Lekakis JP. Long-term prognostic role of flow-mediated dilatation of the brachial artery after acute coronary syndromes without ST elevation. Am J Cardiol 2006; 98: 1424-1428.
31. Fischer D, Rossa S, Landmesser U, Spiekermann S, Engberding N, Hornig B, Drexler H. Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death. Eur Heart J 2005; 26: 65-69.
32. Chan SY, Mancini GB, Kuramoto L, Schulzer M, Frohlich J, Ignaszewski A. The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease. J Am Coll Cardiol 2003; 42: 1037-1043.
33. Frick M, Suessenbacher A, Alber HF, Dichtl W, Ulmer H, Pachinger O, Weidinger F. Prognostic value of brachial artery endothelial function and wall thickness. J Am Coll Cardiol 2005; 46: 1006-1010.
34. Patti G, Pasceri V, Melfi R, Goffredo C, Chello M, DAmbrosio A, Montesanti R, Di Sciascio G. Impaired flow-mediated dilation and risk of restenosis in patients undergoing coronary stent implantation. Circulation 2005; 111: 70-75.
35. Kitta Y, Nakamura T, Kodama Y, Takano H, Umetani K, Fujioka D, Saito Y, Kawabata K, Obata JE, Ichigi Y, Mende A, Kugiyama K. Endothelial vasomotor dysfunction in the brachial artery is associated with late in-stent coronary restenosis. J Am Coll Cardiol 2005; 46: 648-655.
36. Shechter M, Issachar A, Marai I, Koren-Morag N, Freinark D, Shahar Y, Shechter A, Feinberg MS. Long-term association of brachial artery flow-mediated vasodilation and cardiovascular events in middle-Aged subjects with no apparent heart disease. Int J Cardiol 2009; 134: 52-58.
37. Rossi R, Nuzzo A, Origliani G, Modena MG. Prognostic role of flow-mediated dilation and cardiac risk factors in post-menopausal women. J Am Coll Cardiol 2008; 51: 997-1002.
38. Shimbo D, Grahame-Clarke C, Miyake Y, Rodriguez C, Sciacca R, Di Tullio M, Boden-Albala B, Sacco R, Homma S. The association between endothelial dysfunction and cardiovascular outcomes in a population-based multi-ethnic cohort. Atherosclerosis 2007; 192: 197-203.
39. Yeboah J, Crouse JR, Hsu FC, Burke GL, Herrington DM. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation 2007; 115: 2390-2397.
40. Yeboah J, Folsom AR, Burke GL, Johnson C, Polak JF, Post W, Lima JA, Crouse JR, Herrington DM. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation 2009; 120: 502-509.
41. Honda A, Matsuura K, Fukushima N, Tsurumi Y, Kasanuki H, Hagiwara N. Telmisartan induces proliferation of human endothelial progenitor cells via PPARgamma-dependent PI3K/Akt pathway. Atherosclerosis 2009; 205: 376-384.
42. Clasen R, Schupp M, Foryst-Ludwig A, Sprang C, Clemenz M, Krikov M, Thöne-Reineke C, Unger T, Kintscher U. PPARgamma-Activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005; 46: 137-143.
43. Barseghian A, Gawande D, Bajaj M. Adiponectin and vulnerable atherosclerotic plaques. J Am Coll Cardiol 2011; 57: 761-770.
44. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003; 278: 45021-45026.
45. Motoshima H, Wu X, Mahadev K, Goldstein BJ. Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun 2004; 315: 264-267.
46. Takagi H, Umemoto T. Telmisartan increases adiponectin levels: a meta-Analysis and meta-regression of randomized head-to-head trials. Int J Cardiol 2012; 155: 448-451.
47. Terashima M, Kaneda H, Nasu K, Matsuo H, Habara M, Ito T, Tanaka N, Rathore S, Kinoshita Y, Kimura M, Ehara M, Suzuki Y, Suzuki T. Protective effect of telmisartan against endothelial dysfunction after coronary drug-eluting stent implantation in hypertensive patients. JACC Cardiovasc Interv 2012; 5: 182-190.
48. Brillante DG, OSullivan AJ, Brillante RE, Howes LG. Effects of cardiovascular angiotensin II type 1 receptor blockade on nitric oxide synthase inhibition in patients with insulin resistance syndrome. Blood Press 2009; 18: 142-148.
49. Schmieder RE, Delles C, Mimran A, Fauvel JP, Ruilope LM. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care 2007; 30: 1351-1356.
50. Perrone-Filardi P, Corrado L, Brevetti G, Silvestro A, Dellegrottaglie S, Cafiero M, Caiazzo G, Petretta A, Maglione A, Monda C, Guerra G, Marzano A, Cesarano P, Gargiulo P, Chiariello M. Effects of AT1 receptor antagonism with candesartan on endothelial function in patients with hypertension and coronary artery disease. J Clin Hypertens (Greenwich) 2009; 11: 260-265.
51. Souza-Barbosa LA, Ferreira-Melo SE, Ubaid-Girioli S, Arantes Nogueira E, Yugar-Toledo JC, Moreno Jr H. Endothelial vascular function in hypertensive patients after renin-Angiotensin system blockade. J Clin Hypertens (Greenwich) 2006; 8: 803-809; quiz 810-811.
52. Fujimura N, Noma K, Hata T, Soga J, Hidaka T, Idei N, Fujii Y, Mikami S, Maruhashi T, Iwamoto Y, Kihara Y, Chayama K, Kato H, Liao JK, Higashi YROCK Study Group. Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-Associated kinase activity in patients with hypertension. Clin Pharmacol Ther 2012; 91: 289-297.
53. Wei D, He WY, Lv QZ. Effect of nisoldipine and olmesartan on endothelium-dependent vasodilation in essential hypertensive patients. CNS Neurosci Ther 2012; 18: 400-405.
54. Flammer AJ, Hermann F, Wiesli P, Schwegler B, Chenevard R, Hürlimann D, Sudano I, Gay S, Neidhart M, Riesen W, Ruschitzka F, Lüscher TF, Noll G, Lehmann R. Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. J Hypertens 2007; 25: 785-791.
55. Takiguchi S, Ayaori M, Uto-Kondo H, Iizuka M, Sasaki M, Komatsu T, Takase B, Adachi T, Ohsuzu F, Ikewaki K. Olmesartan improves endothelial function in hypertensive patients: link with extracellular superoxide dismutase. Hypertens Res 2011; 34: 686-692.
56. Yilmaz MI, Carrero JJ, Martín-Ventura JL, Sonmez A, Saglam M, Celik T, Yaman H, Yenicesu M, Eyileten T, Moreno JA, Egido J, Blanco-Colio LM. Combined therapy with renin-Angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation. Clin J Am Soc Nephrol 2010; 5: 1174-1181.
57. Shahin Y, Khan JA, Samuel N, Chetter I. Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: a meta-Analysis of randomised controlled trials. Atherosclerosis 2011; 216: 7-16.
58. Deeks JJ, Higgins JP and Altman DG (eds). Chapter 9: analysing data and undertaking meta-Analyses. In: Higgins JP, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011, available from: www.cochrane-handbook.org. Last accessed on 1 February 2014.